Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VVKYV)
| ADC Name |
FZ-AD005
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
FZ-AD005; F0041
Click to Show/Hide
|
|||||
| Organization |
Fudan-Zhangjiang Bio-Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-DLL3 antibody
|
Antibody Info | ||||
| Antigen Name |
Delta-like protein 3 (DLL3)
|
Antigen Info | ||||
| Payload Name |
DXd
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala-PABC double self-immolative linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
BB05
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC